NKGen Biotech (NYSE:NKGN) versus AlloVir (NASDAQ:ALVR) Critical Analysis

Profitability

This table compares NKGen Biotech and AlloVir’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
AlloVir	N/A	-71.03%	-61.27%

Risk and Volatility

NKGen Biotech has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500.

Valuation and Earnings

This table compares NKGen Biotech and AlloVir”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94 million	($2.45)	0.00
AlloVir	N/A	N/A	-$190.42 million	($20.23)	-0.35

AlloVir is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 32.1% of AlloVir shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

NKGen Biotech beats AlloVir on 6 of the 8 factors compared between the two stocks.

About NKGen Biotech

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

About AlloVir

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.